CA2781493A1 - Pharmaceutical compositions for the stimulation of stem cells - Google Patents
Pharmaceutical compositions for the stimulation of stem cells Download PDFInfo
- Publication number
- CA2781493A1 CA2781493A1 CA2781493A CA2781493A CA2781493A1 CA 2781493 A1 CA2781493 A1 CA 2781493A1 CA 2781493 A CA2781493 A CA 2781493A CA 2781493 A CA2781493 A CA 2781493A CA 2781493 A1 CA2781493 A1 CA 2781493A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- previous
- pharmaceutical
- fgf
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 50
- 230000000638 stimulation Effects 0.000 title claims abstract description 9
- 239000002269 analeptic agent Substances 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 95
- 230000000747 cardiac effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 19
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 19
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 19
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 18
- 108010023082 activin A Proteins 0.000 claims description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 15
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 13
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 13
- 210000005003 heart tissue Anatomy 0.000 claims description 13
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 12
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 12
- 102000019034 Chemokines Human genes 0.000 claims description 12
- 108010012236 Chemokines Proteins 0.000 claims description 12
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- LKBSMPFEKIBRGC-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)-4-pyrimidinyl]amino]ethanol Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 LKBSMPFEKIBRGC-UHFFFAOYSA-N 0.000 claims description 11
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 11
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 11
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 210000002216 heart Anatomy 0.000 claims description 10
- 229940100601 interleukin-6 Drugs 0.000 claims description 10
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 9
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 9
- -1 deirudin Chemical compound 0.000 claims description 9
- 239000011164 primary particle Substances 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 229930002330 retinoic acid Natural products 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 239000011163 secondary particle Substances 0.000 claims description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 4
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920001634 Copolyester Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102100020997 Fractalkine Human genes 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102000004858 Growth differentiation factor-9 Human genes 0.000 claims description 4
- 108090001086 Growth differentiation factor-9 Proteins 0.000 claims description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 4
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 4
- 102100026236 Interleukin-8 Human genes 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 4
- 108010056852 Myostatin Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 4
- 102000036693 Thrombopoietin Human genes 0.000 claims description 4
- 108010041111 Thrombopoietin Proteins 0.000 claims description 4
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 239000002077 nanosphere Substances 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- BWRRWBIBNBVHQF-UHFFFAOYSA-N 4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2N=CC=CC=2)=N1 BWRRWBIBNBVHQF-UHFFFAOYSA-N 0.000 claims description 2
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 claims description 2
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 claims description 2
- 102000009840 Angiopoietins Human genes 0.000 claims description 2
- 108010009906 Angiopoietins Proteins 0.000 claims description 2
- 102400000345 Angiotensin-2 Human genes 0.000 claims description 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 2
- 108010081589 Becaplermin Proteins 0.000 claims description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 claims description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 2
- 102100025597 Caspase-4 Human genes 0.000 claims description 2
- 101710090338 Caspase-4 Proteins 0.000 claims description 2
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 108010083698 Chemokine CCL26 Proteins 0.000 claims description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims description 2
- 108010010786 Cholesterol 25-hydroxylase Proteins 0.000 claims description 2
- 102000016917 Complement C1 Human genes 0.000 claims description 2
- 108010028774 Complement C1 Proteins 0.000 claims description 2
- 108010028780 Complement C3 Proteins 0.000 claims description 2
- 102000016918 Complement C3 Human genes 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 2
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims description 2
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 claims description 2
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims description 2
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 2
- 108050005077 Haptoglobin Proteins 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 2
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 2
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims description 2
- 102000000426 Integrin alpha6 Human genes 0.000 claims description 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims description 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 claims description 2
- 102100030335 Midkine Human genes 0.000 claims description 2
- 108010092801 Midkine Proteins 0.000 claims description 2
- 101000878182 Mus musculus Fibroblast growth factor 15 Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 2
- 108700023477 Nucleoside diphosphate kinases Proteins 0.000 claims description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 2
- 102100037765 Periostin Human genes 0.000 claims description 2
- 101710199268 Periostin Proteins 0.000 claims description 2
- 102100035194 Placenta growth factor Human genes 0.000 claims description 2
- 102000011195 Profilin Human genes 0.000 claims description 2
- 108050001408 Profilin Proteins 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- 102000015799 Qa-SNARE Proteins Human genes 0.000 claims description 2
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 claims description 2
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 claims description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 102100030511 Stanniocalcin-1 Human genes 0.000 claims description 2
- 101710142157 Stanniocalcin-1 Proteins 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 102000050707 Syntaxin-11 Human genes 0.000 claims description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 2
- 102400000757 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 2
- 101150109862 WNT-5A gene Proteins 0.000 claims description 2
- 102000043366 Wnt-5a Human genes 0.000 claims description 2
- 108700020483 Wnt-5a Proteins 0.000 claims description 2
- 229950006323 angiotensin ii Drugs 0.000 claims description 2
- 229960003856 argatroban Drugs 0.000 claims description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 108010055460 bivalirudin Proteins 0.000 claims description 2
- 229960001500 bivalirudin Drugs 0.000 claims description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003850 dabigatran Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940076264 interleukin-3 Drugs 0.000 claims description 2
- 229940096397 interleukin-8 Drugs 0.000 claims description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 229960004408 lepirudin Drugs 0.000 claims description 2
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 claims description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 2
- 229960002137 melagatran Drugs 0.000 claims description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 2
- 229960001522 ximelagatran Drugs 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 1
- 102000014702 Haptoglobin Human genes 0.000 claims 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 description 31
- 206010061216 Infarction Diseases 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 210000004165 myocardium Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 210000000107 myocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 6
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004088 microvessel Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 150000002266 vitamin A derivatives Chemical class 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QQAHYSZVJLHCNA-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)pyrimidin-4-yl]amino]ethanol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 QQAHYSZVJLHCNA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000056021 human CTF1 Human genes 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating- agents and at least one pharmaceutically acceptable excipient.
Description
PHARMACEUTICAL COMPOSITIONS FOR THE STIMULATION OF STEM CELLS
TECHNICAL FIELD
[0001] The present invention relates generally to pharmaceutical compositions suitable for targeting tissues and/or organs. In particular, it relates to the treatment of heart diseases through administration of stem cell-stimulating agents to the heart of an individual in need of heart tissue regeneration. In particular, it discloses the use of such stem cell-stimulating agents to improve the regeneration of cardiac tissue from cardiac stem cells in vivo.
DESCRIPTION OF RELATED ART
TECHNICAL FIELD
[0001] The present invention relates generally to pharmaceutical compositions suitable for targeting tissues and/or organs. In particular, it relates to the treatment of heart diseases through administration of stem cell-stimulating agents to the heart of an individual in need of heart tissue regeneration. In particular, it discloses the use of such stem cell-stimulating agents to improve the regeneration of cardiac tissue from cardiac stem cells in vivo.
DESCRIPTION OF RELATED ART
[0002] Myocardial infarction (MI) results in loss of cardiomyocytes, scar formation, ventricular remodeling, and eventually heart failure.
Pharmacologic, catheter-based, and surgical interventions have led to improved survival of patients with coronary artery disease (CAD), although they fail to regenerate dead myocardium. Consequently, reduced mortality is accompanied by increased morbidity because of ischemic heart failure. In recent years, stem cell-based therapy has emerged as a potential new strategy for cardiac repair (Dimmeler S. et al., J Clin Invest 2005, 11, 572-583). The optimal source of cells for repairing damaged myocardium is a topic of intense research.
Important features of stem cells for cardiac regeneration include self renewal, clonogenicity, and the ability to differentiate into cardiomyocytes, endothelial cells and vascular smooth muscle cells.
Pharmacologic, catheter-based, and surgical interventions have led to improved survival of patients with coronary artery disease (CAD), although they fail to regenerate dead myocardium. Consequently, reduced mortality is accompanied by increased morbidity because of ischemic heart failure. In recent years, stem cell-based therapy has emerged as a potential new strategy for cardiac repair (Dimmeler S. et al., J Clin Invest 2005, 11, 572-583). The optimal source of cells for repairing damaged myocardium is a topic of intense research.
Important features of stem cells for cardiac regeneration include self renewal, clonogenicity, and the ability to differentiate into cardiomyocytes, endothelial cells and vascular smooth muscle cells.
[0003] Over the past 10 years, researchers have applied various bone marrow (BM)-derived stem/progenitor cells for cardiac reparative therapy in animal studies, such as lineage negative (fin neg) c-kit positive (c-kit pos) BM
stem cells, (Orlic et al., Nature 2001 ; 410: 701-705; Kajstura et al., Circ.
Res.
2005; 96: 127-137; Rota et al., Proc Natl Acad Sci USA 2007 ; 104: 17783-17788) BM-derived mesenchymal stem cells (MSCs) (Min et al., Ann Thor Surg 2002; 74: 1568-1575; Amado et al., Proc Natl Acad Sci USA 2005; 102:
11474-11479) and endothelial progenitor cells (EPCs) (Cho et al., J Exp Med 2007; 204: 3257-3269; Schuh et al., Basic Res Cardiol 2008; 103:60-77).
Despite these studies showing the differentiation of BM-derived stem/progenitor cells into cells with hallmark features of cardiomyocytes and vascular cells, other studies suggested that the transplanted BM stem cells do not readily acquire a cardiac phenotype in the injured heart (Balsam et al., Nature 2004; 428: 668-673; Murry et al., Nature 2004; 428: 664-668; Nygren et al., Nat Med 2004; 10: 494-501).
stem cells, (Orlic et al., Nature 2001 ; 410: 701-705; Kajstura et al., Circ.
Res.
2005; 96: 127-137; Rota et al., Proc Natl Acad Sci USA 2007 ; 104: 17783-17788) BM-derived mesenchymal stem cells (MSCs) (Min et al., Ann Thor Surg 2002; 74: 1568-1575; Amado et al., Proc Natl Acad Sci USA 2005; 102:
11474-11479) and endothelial progenitor cells (EPCs) (Cho et al., J Exp Med 2007; 204: 3257-3269; Schuh et al., Basic Res Cardiol 2008; 103:60-77).
Despite these studies showing the differentiation of BM-derived stem/progenitor cells into cells with hallmark features of cardiomyocytes and vascular cells, other studies suggested that the transplanted BM stem cells do not readily acquire a cardiac phenotype in the injured heart (Balsam et al., Nature 2004; 428: 668-673; Murry et al., Nature 2004; 428: 664-668; Nygren et al., Nat Med 2004; 10: 494-501).
[0004] Thus, enhancing differentiation of BM-derived stem/progenitor cells after their transplantation remains a great challenge for researchers to effectively use these cells in cardiac regenerative therapy. Other stem cell sources may be used for cardiac regenerative therapy apart from BM-derived stem/ progenitor cells. In particular, resident cardiac stem cells (CSCs) were discovered in the heart itself (Beltrami et al., Cell 2003; 114: 763-776;
Uranek et al., Proc Natl Sci USA 2006; 103: 9226-9231). Because CSCs already reside within the heart and are programmed to generate cardiac tissue, they represent a logical source to exploit in cardiac regenerative therapy, when massive loss of cardiac tissue occurred. Given that CSCs have unique characteristics, the identification of resident CSCs created great excitement and sparked intense hope for myocardial regeneration with cells that are from the heart itself and are thereby inherently programmed to reconstitute cardiac tissue.
Uranek et al., Proc Natl Sci USA 2006; 103: 9226-9231). Because CSCs already reside within the heart and are programmed to generate cardiac tissue, they represent a logical source to exploit in cardiac regenerative therapy, when massive loss of cardiac tissue occurred. Given that CSCs have unique characteristics, the identification of resident CSCs created great excitement and sparked intense hope for myocardial regeneration with cells that are from the heart itself and are thereby inherently programmed to reconstitute cardiac tissue.
[0005] Myocardial repair requires the formation of new myocytes and coronary vessels, and it cannot be accomplished by a cell already fully committed to the myocyte lineage. In the presence of an infarct, the generation of myocytes alone cannot restore contractile performance in the akinetic region; myocytes will not grow or survive in the absence of vessel formation. Arterioles are critical for blood supply, and oxygen delivery is controlled by the capillary network. Similarly, neovasculogenesis alone would not restore the dead myocardium or reinstitute contractile activity in the infarcted portion of the ventricular wall. Observation that CSCs injected locally in the infarcted myocardium of animals repaired the necrotic tissue and improve ventricular function (Beltrami et al., Cell 2003; 114: 763-776; Bearzi et al., Proc Natl Sci USA 2007 ; 104: 14068-14073) has formed the basis of a new paradigm in which CSCs are implicated in the normal renewal of myocytes, endothelial cells, smooth muscle cells, and fibroblasts. In an attempt to develop strategies relevant to the future treatment of patients, new hypotheses have to be raised to move the field in a direction that defines CSCs therapy clinically on an individual basis.
[0006] Various attempts have thus been made to deal with the discovered CSCs for clinical applications. The first approach is isolation, culture, cloning and expansion of CSCs. Such cells would be injected back into the infracted heart in an attempt to regenerate functional myocardium.
However, the scarcity of the CSC cell population, combined to stringent cell culture conditions and poor yield, are limiting factors using this approach.
The other alternative described in the art is the recruitment and differentiation of endogenous CSCs using exogenous agents. However, no clear evidence on the efficacy of this approach has been described casting uncertainty on the capacity to effectively recruit and differentiate CSCs in vivo.
SUMMARY OF THE INVENTION
However, the scarcity of the CSC cell population, combined to stringent cell culture conditions and poor yield, are limiting factors using this approach.
The other alternative described in the art is the recruitment and differentiation of endogenous CSCs using exogenous agents. However, no clear evidence on the efficacy of this approach has been described casting uncertainty on the capacity to effectively recruit and differentiate CSCs in vivo.
SUMMARY OF THE INVENTION
[0007] The present invention provides a totally novel approach to stimulate in vivo resident CSCs and, in one aspect, to commit them into the cardiac lineage, particularly to obtain from them a significant number of satisfactorily functional cells with hallmark features of cardiomyocytes.
[0008] The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem cells-stimulating-agents and at least one pharmaceutically acceptable excipient.
[0009] Said at least two stem cells-stimulating-agents may be selected in the group consisting of TGF(3-1, BMP-4, FGF-2, IGF-1, Activin-A, alpha-thrombin, Cardiotrophin 1, Cardiogenol C and mixtures thereof. In particular, said at least two stem cells-stimulating-agents may be selected in the group consisting of TGF(3-1, BMP-4, FGF-2, IGF-1, Activin-A, Cardiotrophin 1, Cardiogenol C and mixtures thereof.
[0010] The invention also relates to a pharmaceutical cocktail comprising a pharmaceutical composition (B) according to the present invention and a composition (A) comprising at least one pharmaceutically active substance. The composition or cocktail of the present invention allows to provide stimulating agent-guided stem cells which means that resident cardiac stem cells, after having been put into contact with the composition or cocktail, are stimulated to enter into differentiation. Hence, the stimulated stem cells may be committed into a cardiac lineage and may become a cardiomyocyte.
[0011] Within the frame of the present document, and unless indication of the contrary, the terms designated below between quotes have the following definitions.
[0012] As used herein, the term "stimulation or stimulating" refers to recruitment, proliferation, survival and/or differentiation of stem cells.
[0013] As used herein, the terms "cardiac tissue" and "myocardium"
refer to myocytes, blood vessels and fibroblasts.
refer to myocytes, blood vessels and fibroblasts.
[0014] `Cardiac stem cells' (CSCs) , `cardiac progenitor cells' , `resident cardiac stem cells' or `resident cardiac progenitor cells' designate stem cells which are present in the myocardium. They are self-renewing, clonogenic, multipotent and may generate myocardium.
[0015] A `stem cells stimulating agent' is an agent which improves the ability of stem cells, to be recruited to the site to be regenerated, to proliferate and to differentiate into cardiac tissue.
[0016] A `stem cells stimulating agent composition' is a composition comprising at least two stem cell stimulating agents.
[0017] A 'stimulating agent-guided stem cell' is a stem cell which was in contact with a stem cell stimulating agent composition as defined above and further enters into differentiation i.e. is committed into the cardiac lineage.
[0018] The `differentiation' is the process by which a less specialized cell becomes a more specialized cell.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control the meaning of terms of the present invention. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
5 Detailed description of the invention
5 Detailed description of the invention
[0020] In a preferred embodiment, the pharmaceutical composition (B) may comprise at least five stem cells-stimulating-agents selected in the group consisting of TGF(3-1, BMP-4, FGF-2, IGF-1, Activin-A, Cardiotrophin 1, Cardiogenol C and mixtures thereof.
[0021] In particular, the pharmaceutical composition (B) may comprise TGF(3-1, BMP-4, FGF-2, IGF-1, Activin-A, Cardiotrophin 1, and Cardiogenol C.
[0022] Moreover, said pharmaceutical composition (B) may further optionally comprise alpha-thrombin. Said pharmaceutical composition (B) may further comprise thrombin inhibitors, such as hirudin, bivalirudin, lepirudin, deirudin, argatroban, melagatran, ximelagatran, dabigatran, and heparin.
Alpha-thrombin is a coagulant agent. Alternatively, in some cases, said pharmaceutical composition (B) may optionally be free of alpha-thrombin.
Alpha-thrombin is a coagulant agent. Alternatively, in some cases, said pharmaceutical composition (B) may optionally be free of alpha-thrombin.
[0023] The pharmaceutical composition (B) of the present invention may further comprise at least one substance selected in the group consisting of growth factors, cytokines, hormones and combinations thereof. Said at least one substance may be selected in the group consisting of:
- Bone morphogenetic proteins (BMP) such as BMP-1, BMP-2, BMP-5, BMP-6;
- Epidermal growth factor (EGF);
- Erythropoietin (EPO);
- Fibroplast growth factors (FGF) such as FGF-1, FGF-4, FGF-5, FGF-12, FGF-13, FGF-15, FGF-20;
- Granulocyte-colony stimulating factor (G-CSF);
- Granulocyte-macrophage colony stimulating factor (GM-CSF);
- Growth differentiation factor-9 (GDF-9);
- Hepatocyte growth factor (HGF);
- Insuline-like growth factor (IGF) such as IGF-2;
- Myostatin (GDF-8);
- Neurotrophins such as NT-3, NT-4, NT-1 and Nerve growth factor (NGF) ;
- Platelet-derived growth factor (PDGF) such as PDGF-beta, PDGF-AA, PDGF-BB;
- Thrombopoietin (TPO);
- TGF- (Transforming growth factor alpha) - Transforming growth factors R, (TGF- R) such as TGF-G1, TGF-G2, TGF-G3;
- VEGF (Vascular endothelial growth factor) such as VEGF-A, VEGF-C;
- TNF-a, Leukemia inhibitory factor (LIF), interleukin 6 (IL-6), retinoic acid, C SDF-1 (stromal cell-derived factor-1), BDNF (brain-derived neurotrophic factor), Periostin, Angiotensin II, FIt3 Ligand, Glial-Derived Neurotrophic Factor, Heparin, Insulin-Like Growth Factor Binding Protein-3, Insulin- Like Growth Factor Binding Protein-5, Interleukin-3, Interleukin-8, Midkine, Progesterone, Putrescine, Stem Cell Factor, TGF-alpha, Wntl, Wnt3a, Wnt5a, caspase-4, chemokine ligand 1, chemokine ligand 2, chemokine ligand 5, chemokine ligand 7, chemokine ligand 11, chemokine ligand 20, haptoglobin, lectin, cholesterol 25-hydroxylase, syntaxin-8, syntaxin-11, ceruloplasmin, complement component 1, complement component 3, integrin alpha 6, lysosomal acid lipase 1, 9-2 microglobulin, ubiquitin, macrophage migration inhibitory factor, cofilin, cyclophillin A, FKBP12, NDPK, profilin 1, cystatin C, calcyclin, stanniocalcin-1, PGE-2, mpCCL2, IDO, iNOS, HLA-G5, M-CSF, angiopoietin, PIGF, MCP-1, extracellular matrix molecules, CCL2 (MCP-1), CCL3 (MIP-1 a), CCL4 (MIP-1 G), CCL5 (RANTES), CCL7 (MCP-3), CCL20 (MIP-3a), CCL26 (eotaxin-3), CX3CL1 (fractalkine), CXCL5 (ENA-78), CXCL11 (i-TAC), CXCL1 (GROa), CXCL2 (GROG), CXCL8 (IL-8), CCL10 (IP-10) and combinations thereof.
- Bone morphogenetic proteins (BMP) such as BMP-1, BMP-2, BMP-5, BMP-6;
- Epidermal growth factor (EGF);
- Erythropoietin (EPO);
- Fibroplast growth factors (FGF) such as FGF-1, FGF-4, FGF-5, FGF-12, FGF-13, FGF-15, FGF-20;
- Granulocyte-colony stimulating factor (G-CSF);
- Granulocyte-macrophage colony stimulating factor (GM-CSF);
- Growth differentiation factor-9 (GDF-9);
- Hepatocyte growth factor (HGF);
- Insuline-like growth factor (IGF) such as IGF-2;
- Myostatin (GDF-8);
- Neurotrophins such as NT-3, NT-4, NT-1 and Nerve growth factor (NGF) ;
- Platelet-derived growth factor (PDGF) such as PDGF-beta, PDGF-AA, PDGF-BB;
- Thrombopoietin (TPO);
- TGF- (Transforming growth factor alpha) - Transforming growth factors R, (TGF- R) such as TGF-G1, TGF-G2, TGF-G3;
- VEGF (Vascular endothelial growth factor) such as VEGF-A, VEGF-C;
- TNF-a, Leukemia inhibitory factor (LIF), interleukin 6 (IL-6), retinoic acid, C SDF-1 (stromal cell-derived factor-1), BDNF (brain-derived neurotrophic factor), Periostin, Angiotensin II, FIt3 Ligand, Glial-Derived Neurotrophic Factor, Heparin, Insulin-Like Growth Factor Binding Protein-3, Insulin- Like Growth Factor Binding Protein-5, Interleukin-3, Interleukin-8, Midkine, Progesterone, Putrescine, Stem Cell Factor, TGF-alpha, Wntl, Wnt3a, Wnt5a, caspase-4, chemokine ligand 1, chemokine ligand 2, chemokine ligand 5, chemokine ligand 7, chemokine ligand 11, chemokine ligand 20, haptoglobin, lectin, cholesterol 25-hydroxylase, syntaxin-8, syntaxin-11, ceruloplasmin, complement component 1, complement component 3, integrin alpha 6, lysosomal acid lipase 1, 9-2 microglobulin, ubiquitin, macrophage migration inhibitory factor, cofilin, cyclophillin A, FKBP12, NDPK, profilin 1, cystatin C, calcyclin, stanniocalcin-1, PGE-2, mpCCL2, IDO, iNOS, HLA-G5, M-CSF, angiopoietin, PIGF, MCP-1, extracellular matrix molecules, CCL2 (MCP-1), CCL3 (MIP-1 a), CCL4 (MIP-1 G), CCL5 (RANTES), CCL7 (MCP-3), CCL20 (MIP-3a), CCL26 (eotaxin-3), CX3CL1 (fractalkine), CXCL5 (ENA-78), CXCL11 (i-TAC), CXCL1 (GROa), CXCL2 (GROG), CXCL8 (IL-8), CCL10 (IP-10) and combinations thereof.
[0024] The stem cells to be stimulated may be resident cardiac stem cells (CSCs) or circulating stem cells or injected stem cells.
[0025] Said pharmaceutical composition may comprise primary particles. Said primary particles may be selected from the group consisting of alginates, chitosan, dextran, cellulose, liposome, or microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters.
Preferably, said primary particles may encapsulate said at least two stem-cells-stimulating agents of said pharmaceutical composition (B). Hence, said primary particles may encapsulate the stem cells-stimulating agents comprised in the pharmaceutical composition (B). The term "primary" means that the pharmaceutical composition may be encapsulated in a first type of particles as defined above.
Preferably, said primary particles may encapsulate said at least two stem-cells-stimulating agents of said pharmaceutical composition (B). Hence, said primary particles may encapsulate the stem cells-stimulating agents comprised in the pharmaceutical composition (B). The term "primary" means that the pharmaceutical composition may be encapsulated in a first type of particles as defined above.
[0026] Preferably, said pharmaceutical composition (B) may be combined with a composition (A) comprising at least one pharmaceutically active substance to form a pharmaceutical cocktail. In one embodiment, said at least one pharmaceutically active substance may be selected in the group consisting of insulin-like growth factor 1 (IGF-1), hepatocyte growth factor (HGF) and/or variants thereof such as NK1, 1 K1, 1 K2, HP1 1, or HP21, and combinations thereof. In another embodiment, said composition (A) may further comprise SCF-1. Said composition (A) may further comprise secondary particles selected from the group consisting of alginates, chitosan, dextran, cellulose, liposomes, or microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters. Said secondary particles may encapsulate said at least one pharmaceutically active substance. The term "secondary" means that the composition (A) may be encapsulated in a second type of particles as defined above. In addition, said secondary particles may be configured to allow a delivery of the substances encapsulated therein before the delivery of the substance encapsulated in primary particles.
[0027] Said pharmaceutical cocktail may comprise a sample of said composition (B) and a sample of said composition (A). Alternatively, both compositions (A) and (B) may be mixed together in a single sample. When mixed together, compositions (A) and (B) may, however, be administrated to or delivered in the area, or surrounding the area, to be treated separately.
[0028] Said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used as medicine. Alternatively, said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used for the regeneration of cardiac tissue. Alternatively, said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used for the treatment of heart disease, including heart failure, heart ischemia or myocardial infarction.
[0029] In another aspect of the present invention, a process for acting in vivo or ex vivo on CSCs of human or animals is provided. Said process comprises the step of administrating said pharmaceutical composition (B) or said pharmaceutical cocktail of the present invention to said humans or animals.
[0030] The administration of the pharmaceutical composition (B) may follow a preliminary administration of a composition (A) comprising at least one pharmaceutically active substance.
[0031] The administration may be performed by sequential injection of composition A, B or of the cocktail.
[0032] Moreover, the duration between two successive administrations of said pharmaceutical composition or pharmaceutical cocktail of the present invention may be from one hour to 180 days. Each administration may be repeated. Alternatively, each or some administrations of said composition (A) may be optional.
[0033] Hence, said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated parenterally. Moreover, said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated into the circulatory system of a human or animal. Said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated into veins and/or arteries.
[0034] The pharmaceutical composition (B) or pharmaceutical cocktail of the present invention may be administrated to a cardiac tissue. In the preferred embodiment, the administration may be intracoronary for said pharmaceutical composition (B) and intravenous for said preliminary administration of the composition (A).
[0035] TGF(3 as used herein refers to TGFJ3-1, TGF3-2 or TGF3-3 and can be any polypeptide having TGF(3 activity, such as human TGF(3. For example, TGF(3 can be recombinant TGF(3. In one embodiment, TGF(3 can be TGF(3-1. Any appropriate concentration of TGF(3 can be used. For example, between 0.1 and 100 ng of TGF-(3 per ml (e.g., about 33 ng of TGF(31 per ml) can be used.
[0036] BMP can be any polypeptide having BMP activity, such as human BMP. For example, BMP can be recombinant BMP. In one embodiment, BMP can be BMP4. Any concentration of BMP can be used. For example, between 0.1 and 200 ng of BMP per ml (e.g., about 65 ng of BMP4 per ml) can be used.
[0037] FGF-2 can be any polypeptide having FGF-2 activity, such as human FGF-2. For example, FGF-2 can be recombinant FGF-2. Any concentration of FGF-2 can be used. For example, between 0.1 and 200 ng of FGF-2 per ml (e.g., about 65 ng of FGF-2 per ml) can be used.
[0038] IGF-1 can be any polypeptide having IGF-1 activity, such as human IGF-1. For example, IGF-1 can be recombinant IGF-1. Any concentration of IGF-1 can be used. For example, between 1 and 1000 ng of IGF-1 per ml (e.g., about 650 ng of IGF-1 per ml) can be used.
[0039] Activin-A can be any polypeptide having Activin-A activity, such as human Activin-A. For example, Activin-A can be recombinant Activin-A.
Any concentration of Activin-A can be used. For example, between 0.1 and 500 ng of Activin-A per ml (e.g., about 130 ng of Activin-A per ml) can be used.
Any concentration of Activin-A can be used. For example, between 0.1 and 500 ng of Activin-A per ml (e.g., about 130 ng of Activin-A per ml) can be used.
[0040] a-Thrombin can be any polypeptide having a-thrombin activity, such as human a-thrombin. For example, a-thrombin can be recombinant a-thrombin or synthetic a-thrombin. Any concentration of a-thrombin can be used. For example, between 0.05 and 100 units of a-thrombin per ml can be used.
[0041] Cardiotrophin can be any polypeptide having Cardiotrophin activity, such as human Cardiotrophin-1. For example, Cardiotrophin can be recombinant Cardiotrophin. Any concentration of Cardiotrophin can be used.
For example, between 0.05 and 100 ng of Cardiotrophin per ml (e.g., about 5 13 ng of Cardiotrophin-1 per ml) can be used.
For example, between 0.05 and 100 ng of Cardiotrophin per ml (e.g., about 5 13 ng of Cardiotrophin-1 per ml) can be used.
[0042] IL-6 can be any polypeptide having IL-6 activity, such as human IL-6. For example, IL-6 can be recombinant IL-6. Any concentration of IL-6 can be used. For example, between 10 and 400 ng of IL-6 per ml can be used.
10 [0043] Any concentration of Cardiogenol C or a pharmaceutically acceptable salt thereof (e.g., Cardiogenol C hydrochloride) can be used. For example, between 1 and 1000 ng of Cardiogenol C per ml (e.g., about 350 ng per ml of Cardiogenol C) can be used.
[0044] Retinoic acid can be any molecule having retinoic acid activity, such as synthetic retinoic acid, natural retinoic acid, a vitamin A
metabolite, a natural derivative of vitamin A, or a synthetic derivative of vitamin A. Any concentration of retinoic acid can be used. For example, between 1 x 10-7 and 4 x 10-6 pM of retinoic acid can be used.
[0045] In some cases, serum-containing or serum-free media supplemented with TGF(3-1 (e.g., 2.5 ng/ml), BMP4 (e.g., 5 ng/ml), FGF-2 (e.g., 5 ng/ml), IGF-1 (e.g., 50 ng/ml), Activin-A (e.g., 10 ng/ml), Cardiotrophin (e.g., 1 ng/ml), a-thrombin (e.g., 1 Unit/ml), and Cardiogenol C (e.g., 100 nM) can be used. In some cases, the media (e.g., serum-containing or serum-free media) can contain platelet lysate (e.g., a human platelet lysate).
[0046] In some cases, the composition used to stimulate CSCs may contain additional optional factors such as TNF-a, LIF, and VEGF-A.
[0047] TNF-a can be any polypeptide having TNF-a activity, such as human TNF-a. For example, TNF-a can be recombinant TNF-a. Any concentration of TNF-a can be used. For example, between 0.5 and 100 ng of TNF-a per ml can be used.
[0048] LIF can be any polypeptide having LIF activity, such as human LIF. For example, LIF can be recombinant LIF. Any concentration of LIF can be used. For example, between 0.25 and 200 ng of LIF per ml can be used.
[0049] VEGF-A can be any polypeptide having VEGF-A activity, such as human VEGF-A. For example, VEGF-A can be recombinant VEGF-A. Any concentration of VEGF-A can be used. For example, between 0.5 and 400 ng of VEGF-A per ml can be used.
[0050] A composition provided herein can be prepared using any appropriate method. For example, a composition provided herein can be prepared using commercially available stimulating agents. In some cases, a composition provided herein can be prepared to contain cells lysates (e.g., a platelet lysate) or conditioned media from cells such as cardiomyocyte cells or TNF-a-stimulated endodermal cells. For example, a composition provided herein can be prepared using a platelet lysate supplemented with commercially available factors. In some cases, a composition provided herein can be prepared using factors isolated from conditioned medium. In some cases, the factors can be dissolved in media such as cell culture media that does or does not contain serum.
Examples [0051] Tests are performed in acutely infarcted pigs. The following protocol is established. The infarct is performed at TO by 90 minutes left anterior descending (LAD) occlusion followed by a 30 minutes reperfusion. At the end of the reperfusion (Ti), a primary composition is parenterally administrated to the animals by intracoronary delivery distal to the occlusion site. A BrdU loaded osmotic pump is also subcutaneously implanted at T1.
Fourteen days later (T2), a secondary composition is parenterally administrated to the animals. The administration of both compositions can be achieved with different methods of administration such as intravenous injection, intramuscular injection or intracoronary injection. Finally, at 42 days (T3), the euthanasia of the pigs is performed.
[0052] The concentration of constituents are mentioned in brackets.
Two compositions, alone or in combination, are tested:
- Composition A consists of IGF-1 (8 pg in 15ml of Phosphate Buffer Solution (PBS)) and HGF (2 pg in 15 ml of PBS) and - Composition B consists of TGF(3-1 (0.5 pg in 15ml of PBS), BMP4 (1 pg in 15ml of PBS), FGF-2 (1 pg in 15ml of PBS), IGF-1 (10 pg in 15ml of PBS), Activin-A (2 pg in 15m1 of PBS), Cardiotrophin 1 (0.2 pg in 15m1 of PBS) and Cardiogenol C (5.2 pg in 15m1 of PBS).
Both compositions are in a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be phosphate buffered solution (PBS), Hartmann's solution, Ringer's lactate, physiological NaCl (0.9% NaCl) supplemented or not with albumin or with any suitable protein stabilizer composition.
[0053] Five treatment groups of 5 animals each are evaluated.
- Treatment group 1 is a control group and only receives saline solution at T1 and T2.
- Treatment group 2 receives a solution containing the composition A
at T1 and a saline solution at T2, noted as mix A.
- Treatment group 3 receives a solution containing the composition A
at T1 and a solution containing the composition B at T2, noted mix A+B.
- Treatment group 4 receives a solution containing the composition B
at T1 and T2, noted mix B+B.
- Treatment group 5 receives a solution containing the composition B
at T1 and a saline solution at T2, noted mix B.
The protocol is summarized in table 1.
Table 1 Treatment Treatment Treatment Treatment Treatment group 1 group 2 group 3 group 4 group 5 TO: infarct T1:30min Saline A A B B
T2: 2 weeks Saline Saline B B Saline T3: 6 weeks Euthanasia Euthanasia Euthanasia Euthanasia Euthanasia [0054] Blood analyses were performed at different intervals. Blood samples are collected from 2 pigs per treatment group in coronary sinus via jugular vein and venous blood via ear vein. After the primary administration, samples are collected at T1 +5min; T1 +1 h and T1 +6h. After the secondary administration, samples are collected at T2+5min; T2+1 h, T2+6h and T2+24h.
ELISA immunoassays are performed with samples for the quantification of IGF-1 and cardiotrophin 1 concentration.
[0055] Magnetic resonance imaging (MRI) is also performed on all animals at T1+3 days; T2 and T3 to study the scar area, the global left ventricular function, the regional function (wall motion and thickening) and regional perfusion of the ventricular. MRI allows to detect and confirm the presence of new vessels, tissue or cells improving ventricular function.
[0056] Histopathology is also performed to determine the scar area, the identification and quantification of c-kit positive cardiac stem cells.
Histopathology also provides data on distribution, size and density of new vessels and cardiomyocytes. Histopathology allows documenting the repair process at the tissue and cellular level.
[0057] Critical variables have been considered in the analysis of cardiac repair: (1) amount of reconstituted tissue or myocardium mass and coronary vasculature; (2) number and size of restored myocytes and vessels; (3) integration of newly formed myocytes and vessels with the surrounding myocardium; and/or (4) origin of the regenerated myocardial structures.
[0058] Infarct result [0059] Images from MRI imaging were used to evaluate infarct size, infarct weight and the infarct area. Results are listed in Table 2 below.
Table 2 Infarct area Infarct weight Infarct Volume (%) (g) (cm3) Group 1 19.8 15.6 22.0 (Control) Group 2 18.7 15.8 20.7 (Mix A) Group 5 13.7 13.2 15.6 Mix B
Group 4 18.8 22.2 25.2 (Mix B+B) Group 3 9.6 10.3 10.3 Mix A+B
[0060] Experiments demonstrate that the infarct area was about 19.8%
for the control group and about 19% for the group 2 and 4 wherein mix A and mix B+B respectively was used. Surprisingly, using the composition (B) according to the present invention, the infarct area was limited to 13.7% for the group 5 (mix B). Hence, the composition (B) according to the present invention was very efficient to treat infarct, such as myocardial infarction, compared to the other composition.
[0061] In addition, it was also surprisingly observed that when the injection of mix B followed the preliminary injection of mix A, the infarct area was further limited to the value of about 9.6%. This is a result which would not be expected based on the results observed for the other groups. Indeed, mix A used for the group 2 was almost inefficient alone. A synergistic effect was observed by using a pharmaceutical cocktail according to the present invention. This result was confirmed with histopathology and immunohistochemistry testing.
[0062] Histopathology [0063] Results were compiled separately for sections taken in the border zone or within the central areas of the infarct. Results for all the groups are listed in Table 3 below. Data showed in Table 3 are mean from heart slices analyzed for an animal of each group.
Table 3 Border zone Infarct center Infarct/scar Transmurality Infarct/scar Transmurality (%) (%) (%) (%) Group 1 33.0 4.0 73.3 13.3 (Control) Group 2 36.0 6.0 56.7 6.7 (Mix A) Group 5 26.0 6.0 30.0 0.0 (Mix B) Group 4 31.4 12.9 70.0 10.0 Mix B+B
Group 3 20.0 0.0 25.0 0.0 Mix A+B
[0064] The ratio between the infarct and scar size represents the infarct size while the transmurality is a parameter establishing whether the infarct is strongly localized at the external surface of the myocardium or it extends throughout the internal surface of the myocardium. The higher is the transmurality value, the larger is the infarct.
[0065] With regard to the border zone of the infarct, Table 3 shows that mix A, mix B+B or control mix had almost no impact on the infarct size. In those cases, the ratio between the infarct and scar size ranged from 31.4% to 5 36.0%. On the contrary, when the composition according to the present invention is used (i.e. mix B), the ratio between infarct and scar size was surprisingly decreased to 26%. This value can be further decreased up to 20%
when the pharmaceutical cocktail according to the present invention (i.e. mix A+B) was used. This experiment demonstrates that the present 10 pharmaceutical composition and pharmaceutical cocktail are effective to treat heart disease. This was also confirmed when experiments were performed in the infarct zone.
[0066] Furthermore, it was surprisingly demonstrated that transmurality is reduced with mix B alone or mix A+B. This means that the composition (B) 15 of the present invention alone or when combined with composition (A) allows limiting the expansion of the infarct to the external surface of the myocardium.
This is another evidence that the pharmaceutical composition and the pharmaceutical cocktail according to the present invention are powerful compositions to treat heart diseases or troubles.
[0067] Hence, it is clear from the above-described experiments that both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for the treatment of heart failure secondary to myocardial ischemia, ischemia or myocardial infarction.
[0068] Immunohistochemistry [0069] Tests were performed to evaluate, within the infarct sections, the microvessel density (vWF-positive vessels/mm2), BrdU positive cells and c-kit positive cells. The quantification of microvessel density using von Willebrand factor (vWF) allows determining the amount of new blood vessels created in the infarct zone. BrdU positive cells tests represent the proliferation of cells, including cardiac cells. C-kit positive cells tests show the amount of CSCs within the selected infarct sections. Results are listed in Table 4. These testing were only performed for group 1 (Control group), group 3 (Mix A + B) and group 5 (Mix B).
Table 4 Group 1 Group 3 Group 5 (Control) (Mix A+B) (Mix B) Microvessel Density 27.9 34.3 34.3 (vWF-positive vessels/mm2) BrdU positive cells (%) 22.1 52.7 36.0 c-kit positive cells (%) 1.9 1.2 1.8 [0070] Results show that when compositions (A) and (B) in combination or composition (B) alone, according to the invention, are injected in the heart, they have great impact on cardiac stem cells stimulation or cardiac cells proliferation. Indeed, microvessel density is enhanced and new blood vessels were created upon stimulation with the present composition or present cocktail. Results obtained with groups 3 or 5 reached 34.2 and 34.3 respectively, compared to 27.9 for the control group. This is confirmed with BrdU positive cells test which shows that cells proliferation was enhanced with the composition of the present invention and that strong cellular activity was observed. When Mix B was injected, 36.0% of BrdU positive cells were observed compared to only 22.1 % for the control group. This clearly highlights that the pharmaceutical composition according to the present invention promotes cellular proliferation and thus the formation of new myocytes and vessels with the surrounding myocardium. This can be further enhanced when the pharmaceutical cocktail according to the present invention was used. A
value of 52.7% was reached with such cocktail. Hence, both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for improving heart tissue regeneration.
[0071] The ability of the pharmaceutical cocktail to induce and to promote the CSCs activation and proliferation was confirmed with c-kit positive cells test. C-kit positive cells test allows demonstrating that resident CSCs are consumed since their amount has significantly decreased when mix A+B was used compared to the control group. Hence, the regenerated myocardial structures are originated from resident cardiac stem cells. The present composition and/or cocktail are effective for in vivo stimulation of resident cardiac stem cells.
[0072] The terms and descriptions used herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that many variations are possible within the spirit and scope of the invention as defined in the following claims, and their equivalents, in which all terms are to be understood in their broadest possible sense unless otherwise indicated. As a consequence, all modifications and alterations will occur to others upon reading and understanding the previous description of the invention. In particular, dimensions, materials, and other parameters, given in the above description may vary depending on the needs of the application.
10 [0043] Any concentration of Cardiogenol C or a pharmaceutically acceptable salt thereof (e.g., Cardiogenol C hydrochloride) can be used. For example, between 1 and 1000 ng of Cardiogenol C per ml (e.g., about 350 ng per ml of Cardiogenol C) can be used.
[0044] Retinoic acid can be any molecule having retinoic acid activity, such as synthetic retinoic acid, natural retinoic acid, a vitamin A
metabolite, a natural derivative of vitamin A, or a synthetic derivative of vitamin A. Any concentration of retinoic acid can be used. For example, between 1 x 10-7 and 4 x 10-6 pM of retinoic acid can be used.
[0045] In some cases, serum-containing or serum-free media supplemented with TGF(3-1 (e.g., 2.5 ng/ml), BMP4 (e.g., 5 ng/ml), FGF-2 (e.g., 5 ng/ml), IGF-1 (e.g., 50 ng/ml), Activin-A (e.g., 10 ng/ml), Cardiotrophin (e.g., 1 ng/ml), a-thrombin (e.g., 1 Unit/ml), and Cardiogenol C (e.g., 100 nM) can be used. In some cases, the media (e.g., serum-containing or serum-free media) can contain platelet lysate (e.g., a human platelet lysate).
[0046] In some cases, the composition used to stimulate CSCs may contain additional optional factors such as TNF-a, LIF, and VEGF-A.
[0047] TNF-a can be any polypeptide having TNF-a activity, such as human TNF-a. For example, TNF-a can be recombinant TNF-a. Any concentration of TNF-a can be used. For example, between 0.5 and 100 ng of TNF-a per ml can be used.
[0048] LIF can be any polypeptide having LIF activity, such as human LIF. For example, LIF can be recombinant LIF. Any concentration of LIF can be used. For example, between 0.25 and 200 ng of LIF per ml can be used.
[0049] VEGF-A can be any polypeptide having VEGF-A activity, such as human VEGF-A. For example, VEGF-A can be recombinant VEGF-A. Any concentration of VEGF-A can be used. For example, between 0.5 and 400 ng of VEGF-A per ml can be used.
[0050] A composition provided herein can be prepared using any appropriate method. For example, a composition provided herein can be prepared using commercially available stimulating agents. In some cases, a composition provided herein can be prepared to contain cells lysates (e.g., a platelet lysate) or conditioned media from cells such as cardiomyocyte cells or TNF-a-stimulated endodermal cells. For example, a composition provided herein can be prepared using a platelet lysate supplemented with commercially available factors. In some cases, a composition provided herein can be prepared using factors isolated from conditioned medium. In some cases, the factors can be dissolved in media such as cell culture media that does or does not contain serum.
Examples [0051] Tests are performed in acutely infarcted pigs. The following protocol is established. The infarct is performed at TO by 90 minutes left anterior descending (LAD) occlusion followed by a 30 minutes reperfusion. At the end of the reperfusion (Ti), a primary composition is parenterally administrated to the animals by intracoronary delivery distal to the occlusion site. A BrdU loaded osmotic pump is also subcutaneously implanted at T1.
Fourteen days later (T2), a secondary composition is parenterally administrated to the animals. The administration of both compositions can be achieved with different methods of administration such as intravenous injection, intramuscular injection or intracoronary injection. Finally, at 42 days (T3), the euthanasia of the pigs is performed.
[0052] The concentration of constituents are mentioned in brackets.
Two compositions, alone or in combination, are tested:
- Composition A consists of IGF-1 (8 pg in 15ml of Phosphate Buffer Solution (PBS)) and HGF (2 pg in 15 ml of PBS) and - Composition B consists of TGF(3-1 (0.5 pg in 15ml of PBS), BMP4 (1 pg in 15ml of PBS), FGF-2 (1 pg in 15ml of PBS), IGF-1 (10 pg in 15ml of PBS), Activin-A (2 pg in 15m1 of PBS), Cardiotrophin 1 (0.2 pg in 15m1 of PBS) and Cardiogenol C (5.2 pg in 15m1 of PBS).
Both compositions are in a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be phosphate buffered solution (PBS), Hartmann's solution, Ringer's lactate, physiological NaCl (0.9% NaCl) supplemented or not with albumin or with any suitable protein stabilizer composition.
[0053] Five treatment groups of 5 animals each are evaluated.
- Treatment group 1 is a control group and only receives saline solution at T1 and T2.
- Treatment group 2 receives a solution containing the composition A
at T1 and a saline solution at T2, noted as mix A.
- Treatment group 3 receives a solution containing the composition A
at T1 and a solution containing the composition B at T2, noted mix A+B.
- Treatment group 4 receives a solution containing the composition B
at T1 and T2, noted mix B+B.
- Treatment group 5 receives a solution containing the composition B
at T1 and a saline solution at T2, noted mix B.
The protocol is summarized in table 1.
Table 1 Treatment Treatment Treatment Treatment Treatment group 1 group 2 group 3 group 4 group 5 TO: infarct T1:30min Saline A A B B
T2: 2 weeks Saline Saline B B Saline T3: 6 weeks Euthanasia Euthanasia Euthanasia Euthanasia Euthanasia [0054] Blood analyses were performed at different intervals. Blood samples are collected from 2 pigs per treatment group in coronary sinus via jugular vein and venous blood via ear vein. After the primary administration, samples are collected at T1 +5min; T1 +1 h and T1 +6h. After the secondary administration, samples are collected at T2+5min; T2+1 h, T2+6h and T2+24h.
ELISA immunoassays are performed with samples for the quantification of IGF-1 and cardiotrophin 1 concentration.
[0055] Magnetic resonance imaging (MRI) is also performed on all animals at T1+3 days; T2 and T3 to study the scar area, the global left ventricular function, the regional function (wall motion and thickening) and regional perfusion of the ventricular. MRI allows to detect and confirm the presence of new vessels, tissue or cells improving ventricular function.
[0056] Histopathology is also performed to determine the scar area, the identification and quantification of c-kit positive cardiac stem cells.
Histopathology also provides data on distribution, size and density of new vessels and cardiomyocytes. Histopathology allows documenting the repair process at the tissue and cellular level.
[0057] Critical variables have been considered in the analysis of cardiac repair: (1) amount of reconstituted tissue or myocardium mass and coronary vasculature; (2) number and size of restored myocytes and vessels; (3) integration of newly formed myocytes and vessels with the surrounding myocardium; and/or (4) origin of the regenerated myocardial structures.
[0058] Infarct result [0059] Images from MRI imaging were used to evaluate infarct size, infarct weight and the infarct area. Results are listed in Table 2 below.
Table 2 Infarct area Infarct weight Infarct Volume (%) (g) (cm3) Group 1 19.8 15.6 22.0 (Control) Group 2 18.7 15.8 20.7 (Mix A) Group 5 13.7 13.2 15.6 Mix B
Group 4 18.8 22.2 25.2 (Mix B+B) Group 3 9.6 10.3 10.3 Mix A+B
[0060] Experiments demonstrate that the infarct area was about 19.8%
for the control group and about 19% for the group 2 and 4 wherein mix A and mix B+B respectively was used. Surprisingly, using the composition (B) according to the present invention, the infarct area was limited to 13.7% for the group 5 (mix B). Hence, the composition (B) according to the present invention was very efficient to treat infarct, such as myocardial infarction, compared to the other composition.
[0061] In addition, it was also surprisingly observed that when the injection of mix B followed the preliminary injection of mix A, the infarct area was further limited to the value of about 9.6%. This is a result which would not be expected based on the results observed for the other groups. Indeed, mix A used for the group 2 was almost inefficient alone. A synergistic effect was observed by using a pharmaceutical cocktail according to the present invention. This result was confirmed with histopathology and immunohistochemistry testing.
[0062] Histopathology [0063] Results were compiled separately for sections taken in the border zone or within the central areas of the infarct. Results for all the groups are listed in Table 3 below. Data showed in Table 3 are mean from heart slices analyzed for an animal of each group.
Table 3 Border zone Infarct center Infarct/scar Transmurality Infarct/scar Transmurality (%) (%) (%) (%) Group 1 33.0 4.0 73.3 13.3 (Control) Group 2 36.0 6.0 56.7 6.7 (Mix A) Group 5 26.0 6.0 30.0 0.0 (Mix B) Group 4 31.4 12.9 70.0 10.0 Mix B+B
Group 3 20.0 0.0 25.0 0.0 Mix A+B
[0064] The ratio between the infarct and scar size represents the infarct size while the transmurality is a parameter establishing whether the infarct is strongly localized at the external surface of the myocardium or it extends throughout the internal surface of the myocardium. The higher is the transmurality value, the larger is the infarct.
[0065] With regard to the border zone of the infarct, Table 3 shows that mix A, mix B+B or control mix had almost no impact on the infarct size. In those cases, the ratio between the infarct and scar size ranged from 31.4% to 5 36.0%. On the contrary, when the composition according to the present invention is used (i.e. mix B), the ratio between infarct and scar size was surprisingly decreased to 26%. This value can be further decreased up to 20%
when the pharmaceutical cocktail according to the present invention (i.e. mix A+B) was used. This experiment demonstrates that the present 10 pharmaceutical composition and pharmaceutical cocktail are effective to treat heart disease. This was also confirmed when experiments were performed in the infarct zone.
[0066] Furthermore, it was surprisingly demonstrated that transmurality is reduced with mix B alone or mix A+B. This means that the composition (B) 15 of the present invention alone or when combined with composition (A) allows limiting the expansion of the infarct to the external surface of the myocardium.
This is another evidence that the pharmaceutical composition and the pharmaceutical cocktail according to the present invention are powerful compositions to treat heart diseases or troubles.
[0067] Hence, it is clear from the above-described experiments that both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for the treatment of heart failure secondary to myocardial ischemia, ischemia or myocardial infarction.
[0068] Immunohistochemistry [0069] Tests were performed to evaluate, within the infarct sections, the microvessel density (vWF-positive vessels/mm2), BrdU positive cells and c-kit positive cells. The quantification of microvessel density using von Willebrand factor (vWF) allows determining the amount of new blood vessels created in the infarct zone. BrdU positive cells tests represent the proliferation of cells, including cardiac cells. C-kit positive cells tests show the amount of CSCs within the selected infarct sections. Results are listed in Table 4. These testing were only performed for group 1 (Control group), group 3 (Mix A + B) and group 5 (Mix B).
Table 4 Group 1 Group 3 Group 5 (Control) (Mix A+B) (Mix B) Microvessel Density 27.9 34.3 34.3 (vWF-positive vessels/mm2) BrdU positive cells (%) 22.1 52.7 36.0 c-kit positive cells (%) 1.9 1.2 1.8 [0070] Results show that when compositions (A) and (B) in combination or composition (B) alone, according to the invention, are injected in the heart, they have great impact on cardiac stem cells stimulation or cardiac cells proliferation. Indeed, microvessel density is enhanced and new blood vessels were created upon stimulation with the present composition or present cocktail. Results obtained with groups 3 or 5 reached 34.2 and 34.3 respectively, compared to 27.9 for the control group. This is confirmed with BrdU positive cells test which shows that cells proliferation was enhanced with the composition of the present invention and that strong cellular activity was observed. When Mix B was injected, 36.0% of BrdU positive cells were observed compared to only 22.1 % for the control group. This clearly highlights that the pharmaceutical composition according to the present invention promotes cellular proliferation and thus the formation of new myocytes and vessels with the surrounding myocardium. This can be further enhanced when the pharmaceutical cocktail according to the present invention was used. A
value of 52.7% was reached with such cocktail. Hence, both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for improving heart tissue regeneration.
[0071] The ability of the pharmaceutical cocktail to induce and to promote the CSCs activation and proliferation was confirmed with c-kit positive cells test. C-kit positive cells test allows demonstrating that resident CSCs are consumed since their amount has significantly decreased when mix A+B was used compared to the control group. Hence, the regenerated myocardial structures are originated from resident cardiac stem cells. The present composition and/or cocktail are effective for in vivo stimulation of resident cardiac stem cells.
[0072] The terms and descriptions used herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that many variations are possible within the spirit and scope of the invention as defined in the following claims, and their equivalents, in which all terms are to be understood in their broadest possible sense unless otherwise indicated. As a consequence, all modifications and alterations will occur to others upon reading and understanding the previous description of the invention. In particular, dimensions, materials, and other parameters, given in the above description may vary depending on the needs of the application.
Claims (32)
1. A human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem cells-stimulating-agents and at least one pharmaceutically acceptable excipient.
2. A pharmaceutical composition according to claim 1, wherein the at least two stem-cells-stimulating-agents are selected from the group consisting of TGF.beta.-1, BMP-4, FGF-2, IGF-1, Activin-A, Cardiotrophin 1, Cardiogenol C and mixtures thereof.
3. A pharmaceutical composition according to claim 2, wherein the stem-cells-stimulating-agents are TGF.beta.-1, BMP-4, FGF-2, IGF-1, Activin-A, Cardiotrophin 1, and Cardiogenol C.
4. A pharmaceutical composition according to any of the previous claims, wherein the composition further comprises thrombin inhibitors selected from the group consisting of hirudin, bivalirudin, lepirudin, deirudin, argatroban, melagatran, ximelagatran, dabigatran, and heparin.
5. A pharmaceutical composition according to any of previous claims, which further comprises at least one substance selected in the group consisting of growth factors, cytokines, hormones and combinations thereof.
6. A pharmaceutical composition according to claim 5, wherein the at least one substance is selected in the group consisting of - Bone morphogenetic proteins (BMP) such as BMP-1, BMP-2, BMP-5, BMP-6;
- Epidermal growth factor (EGF);
- Erythropoietin (EPO);
- Fibroplast growth factors (FGF) such as FGF-1, FGF-4, FGF-5, FGF-12, FGF-13, FGF-15, FGF-20;
- Granulocyte-colony stimulating factor (G-CSF);
- Granulocyte-macrophage colony stimulating factor (GM-CSF);
- Growth differentiation factor-9 (GDF-9);
- Hepatocyte growth factor (HGF);
- Insuline-like growth factor (IGF) such as IGF-2;
- Myostatin (GDF-8);
- Neurotrophins such as NT-3, NT-4, NT-1 and Nerve growth factor (NGF) ;
- Platelet-derived growth factor (PDGF) such as PDGF-beta, PDGF-AA, PDGF-BB;
- Thrombopoietin (TPO);
- TGF- (Transforming growth factor alpha) - Transforming growth factors .beta., (TGF- .beta.) such as TGF-.beta.1, TGF-.beta.2, TGF-.beta.3;
- VEGF (Vascular endothelial growth factor) such as VEGF-A, VEGF-C;
- TNF-.alpha., Leukemia inhibitory factor (LIF), interleukin 6 (IL-6), retinoic acid, C SDF-1 (stromal cell-derived factor-1), BDNF (brain-derived neurotrophic factor), Periostin, Angiotensin II, FIt3 Ligand, Glial-Derived Neurotrophic Factor, Insulin-Like Growth Factor Binding Protein-3, Insulin- Like Growth Factor Binding Protein-5, Interleukin-3, Interleukin-8, Midkine, Progesterone, Putrescine, Stem Cell Factor, TGF-alpha, Wntl, Wnt3a, Wnt5a, caspase-4, chemokine ligand 1, chemokine ligand 2, chemokine ligand 5, chemokine ligand 7, chemokine ligand 11, chemokine ligand 20, haptoglobin, lectin, cholesterol 25-hydroxylase, syntaxin-8, syntaxin-11, ceruloplasmin, complement component 1, complement component 3, integrin alpha 6, lysosomal acid lipase 1, 9-2 microglobulin, ubiquitin, macrophage migration inhibitory factor, cofilin, cyclophillin A, FKBP12, NDPK, profilin 1, cystatin C, calcyclin, stanniocalcin-1, PGE-2, mpCCL2, IDO, iNOS, HLA-G5, M-CSF, angiopoietin, PIGF, MCP-1, extracellular matrix molecules, CCL2 (MCP-1), CCL3 (MIP-1 .alpha.), CCL4 (MIP-1.beta.), CCL5 (RANTES), CCL7 (MCP-3), CCL20 (MIP-3.alpha.), CCL26 (eotaxin-3), CX3CL1 (fractalkine), CXCL5 (ENA-78), CXCL11 (i-TAC), CXCL1 (GRO.alpha.), CXCL2 (GRO.beta.), CXCL8 (IL-8), CCL10 (IP-10) and combinations thereof.
- Epidermal growth factor (EGF);
- Erythropoietin (EPO);
- Fibroplast growth factors (FGF) such as FGF-1, FGF-4, FGF-5, FGF-12, FGF-13, FGF-15, FGF-20;
- Granulocyte-colony stimulating factor (G-CSF);
- Granulocyte-macrophage colony stimulating factor (GM-CSF);
- Growth differentiation factor-9 (GDF-9);
- Hepatocyte growth factor (HGF);
- Insuline-like growth factor (IGF) such as IGF-2;
- Myostatin (GDF-8);
- Neurotrophins such as NT-3, NT-4, NT-1 and Nerve growth factor (NGF) ;
- Platelet-derived growth factor (PDGF) such as PDGF-beta, PDGF-AA, PDGF-BB;
- Thrombopoietin (TPO);
- TGF- (Transforming growth factor alpha) - Transforming growth factors .beta., (TGF- .beta.) such as TGF-.beta.1, TGF-.beta.2, TGF-.beta.3;
- VEGF (Vascular endothelial growth factor) such as VEGF-A, VEGF-C;
- TNF-.alpha., Leukemia inhibitory factor (LIF), interleukin 6 (IL-6), retinoic acid, C SDF-1 (stromal cell-derived factor-1), BDNF (brain-derived neurotrophic factor), Periostin, Angiotensin II, FIt3 Ligand, Glial-Derived Neurotrophic Factor, Insulin-Like Growth Factor Binding Protein-3, Insulin- Like Growth Factor Binding Protein-5, Interleukin-3, Interleukin-8, Midkine, Progesterone, Putrescine, Stem Cell Factor, TGF-alpha, Wntl, Wnt3a, Wnt5a, caspase-4, chemokine ligand 1, chemokine ligand 2, chemokine ligand 5, chemokine ligand 7, chemokine ligand 11, chemokine ligand 20, haptoglobin, lectin, cholesterol 25-hydroxylase, syntaxin-8, syntaxin-11, ceruloplasmin, complement component 1, complement component 3, integrin alpha 6, lysosomal acid lipase 1, 9-2 microglobulin, ubiquitin, macrophage migration inhibitory factor, cofilin, cyclophillin A, FKBP12, NDPK, profilin 1, cystatin C, calcyclin, stanniocalcin-1, PGE-2, mpCCL2, IDO, iNOS, HLA-G5, M-CSF, angiopoietin, PIGF, MCP-1, extracellular matrix molecules, CCL2 (MCP-1), CCL3 (MIP-1 .alpha.), CCL4 (MIP-1.beta.), CCL5 (RANTES), CCL7 (MCP-3), CCL20 (MIP-3.alpha.), CCL26 (eotaxin-3), CX3CL1 (fractalkine), CXCL5 (ENA-78), CXCL11 (i-TAC), CXCL1 (GRO.alpha.), CXCL2 (GRO.beta.), CXCL8 (IL-8), CCL10 (IP-10) and combinations thereof.
7. A pharmaceutical composition according to any of the previous claims wherein stem cells to be stimulated are resident cardiac stem cells or circulating stem cells or injected stem cells.
8. A pharmaceutical composition according to any of the previous claims, which comprises primary particles.
9. A pharmaceutical composition according to claim 8 wherein primary particles are selected from the group consisting of alginates, chitosan, dextran, cellulose, liposome, and microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters.
10. A pharmaceutical composition according to claims 8 or 9 wherein primary particles encapsulate the stem cells-stimulating agents of said pharmaceutical composition.
11. A pharmaceutical cocktail characterized in that it comprises a pharmaceutical composition (B) according to any of the previous claims and a composition (A) comprising at least one pharmaceutically active substance.
12. A pharmaceutical cocktail according to claim 11 characterized in that said at least one pharmaceutically active substance is selected from the group consisting of insulin-like growth factor 1(IGF-1), hepatocyte growth factor (HGF) and/or variants thereof such as NK1, 1K1, 1K2, HP11, or HP21, and combinations thereof.
13. A pharmaceutical cocktail according to claims 11 or 12, characterized in that said at least one pharmaceutically active substance further comprises SCF-1.
14. A pharmaceutical cocktail according to any of the previous claims 11 to 13 characterized in that said composition (A) further comprises secondary particles selected from the group consisting of alginates, chitosan, dextran, cellulose, liposome, or microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters.
15. A pharmaceutical cocktail according to claim 14 wherein secondary particles encapsulate said at least one pharmaceutically active substance.
16. A pharmaceutical cocktail according to claims 14 or 15 wherein said secondary particles are configured to allow a delivery of the substance encapsulated therein before the delivery of the substance encapsulated in primary particles.
17. A pharmaceutical composition according to any of claims 1 to 10 or a pharmaceutical cocktail according to any of claims 11 to 16 for use as medicine.
18. A pharmaceutical composition according to any of claims 1 to 10 or a pharmaceutical cocktail according to any of claims 11 to 16 for use in the regeneration of cardiac tissue.
19. A pharmaceutical composition according to any of claims 1 to 10 or a pharmaceutical cocktail according to any of claims 11 to 16 for use in the treatment of degeneration of cardiac tissue.
20. A pharmaceutical composition according to any of claims 1 to 10 or a pharmaceutical cocktail according to any of claims 11 to 16 for use in the treatment of heart disease, including heart failure, heart ischemia or myocardial infarction.
21. A process for acting in vivo or ex vivo on cardiac stem cells of human or animals wherein a pharmaceutical composition (B) according to claims 1 to 10 is administrated to said human or animals.
22. A process according to claim 21, wherein the administration of the composition (B) follows a preliminary administration of the composition (A) comprising at least one pharmaceutically active substance.
23. A process according to claims 21 or 22, wherein the administration is performed by injection.
24. A process according to any of the previous claims 21 to 23 wherein the administration is a sequential injection.
25. A process according to any of the previous claims 21 to 24, wherein the duration between two successive administrations of said pharmaceutical composition (B) according to any of the previous claims 1 to 10 is from 1 hour to 180 days.
26. A process according to any of previous claims 21 to 25, wherein each administration is repeated.
27. A process according to any of previous claims 21 to 26 wherein the compositions (A) or (B) are parenterally administrated.
28. A process according to any of previous claims 21 to 27 wherein the compositions (A) or (B) are administered into the circulatory system of a human or animal.
29. A process according to any of previous claims 21 to 28, wherein the compositions (A) or (B) are administered into veins and/or arteries.
30. A process according to any of the previous claims 21 to 29 wherein the compositions (A) or (B) are administered to a cardiac tissue.
31. A process according to any of previous claims 21 to 30 wherein the administration is intracoronary for said pharmaceutical composition (B) and intravenous for said preliminary administration of the composition (A).
32. A process according to any of previous claims 21 to 26 wherein each administration of said composition (A) is optional.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2009066251 | 2009-12-02 | ||
| EPPCT/EP2009/066251 | 2009-12-02 | ||
| PCT/EP2010/068700 WO2011067317A1 (en) | 2009-12-02 | 2010-12-02 | Pharmaceutical compositions for the stimulation of stem cells. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2781493A1 true CA2781493A1 (en) | 2011-06-09 |
Family
ID=42316097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2781493A Abandoned CA2781493A1 (en) | 2009-12-02 | 2010-12-02 | Pharmaceutical compositions for the stimulation of stem cells |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP2013512877A (en) |
| KR (1) | KR20120099751A (en) |
| CN (1) | CN102711798A (en) |
| AU (1) | AU2010326633A1 (en) |
| BR (1) | BR112012013164A2 (en) |
| CA (1) | CA2781493A1 (en) |
| IL (1) | IL219901A0 (en) |
| MX (1) | MX2012005976A (en) |
| NZ (1) | NZ599930A (en) |
| RU (1) | RU2012120834A (en) |
| TW (1) | TW201141510A (en) |
| WO (1) | WO2011067317A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101836029B1 (en) * | 2014-07-07 | 2018-03-08 | 메디포스트(주) | An Ability of Conditioned Media of stimulated Stem cells for Hair-growth and the Use thereof |
| CN105079791A (en) * | 2015-09-18 | 2015-11-25 | 郑榆坤 | Composition for stimulating endogenous stem cells in vivo and application of composition |
| RU2634576C1 (en) * | 2016-10-24 | 2017-10-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Method for tissue regeneration stimulation |
| CN107050428B (en) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | FGF20 drug and its application in the treatment of brain trauma |
| CN107648592B (en) * | 2017-11-13 | 2021-05-14 | 深圳市喆邦生物工程有限公司 | Application of chemokine CCL4 in preparation of medicine for treating bone fracture |
| RU2686718C1 (en) * | 2018-03-12 | 2019-04-30 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Agent stimulating mesenchymal progenitor cell functions in vitro |
| KR102106710B1 (en) | 2018-10-11 | 2020-05-04 | 강원대학교산학협력단 | hematopoietic differentiation of human pluripotent stem cells in a developmental stage-specific manner |
| CN111195350A (en) * | 2020-01-15 | 2020-05-26 | 重庆大学 | Application of combination of IGF1 and IGF1Ec24 in preparation of medicines for promoting tissue repair and regeneration |
| WO2021187895A1 (en) * | 2020-03-17 | 2021-09-23 | 주식회사 히에라바이오 | Composition for preventing or treating ischemic diseases, comprising cardiac stem cells |
| CN111621525B (en) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Application of STX1B gene in promoting growth and differentiation of human adipose-derived mesenchymal stem cells |
| KR20240131080A (en) * | 2023-02-23 | 2024-08-30 | 서울대학교산학협력단 | Medium composition for culture of extraembryonic endoderm stem cells |
| CN116836920B (en) * | 2023-08-21 | 2024-05-24 | 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 | Serum-free culture medium and method for preparing mesenchymal stem cells by using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2626234T3 (en) * | 2004-07-30 | 2017-07-24 | Mayo Foundation For Medical Education And Research | Cardiovascular tissue treatment |
| CA2590338A1 (en) * | 2005-01-25 | 2006-08-03 | Five Prime Therapeutics, Inc. | Compositions and methods for treating cardiac conditions |
| US9765298B2 (en) * | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| US8481075B2 (en) * | 2007-12-13 | 2013-07-09 | Beijing Shengyiyao Science & Technology Development Co. Ltd. | Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines |
-
2010
- 2010-12-02 AU AU2010326633A patent/AU2010326633A1/en not_active Abandoned
- 2010-12-02 JP JP2012541498A patent/JP2013512877A/en not_active Withdrawn
- 2010-12-02 KR KR1020127017238A patent/KR20120099751A/en not_active Application Discontinuation
- 2010-12-02 TW TW099141986A patent/TW201141510A/en unknown
- 2010-12-02 CA CA2781493A patent/CA2781493A1/en not_active Abandoned
- 2010-12-02 RU RU2012120834/15A patent/RU2012120834A/en not_active Application Discontinuation
- 2010-12-02 BR BR112012013164A patent/BR112012013164A2/en not_active IP Right Cessation
- 2010-12-02 NZ NZ599930A patent/NZ599930A/en not_active IP Right Cessation
- 2010-12-02 CN CN201080053800XA patent/CN102711798A/en active Pending
- 2010-12-02 MX MX2012005976A patent/MX2012005976A/en unknown
- 2010-12-02 WO PCT/EP2010/068700 patent/WO2011067317A1/en active Application Filing
-
2012
- 2012-05-20 IL IL219901A patent/IL219901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012120834A (en) | 2014-01-20 |
| TW201141510A (en) | 2011-12-01 |
| MX2012005976A (en) | 2012-06-25 |
| WO2011067317A1 (en) | 2011-06-09 |
| CN102711798A (en) | 2012-10-03 |
| JP2013512877A (en) | 2013-04-18 |
| IL219901A0 (en) | 2012-07-31 |
| NZ599930A (en) | 2014-04-30 |
| BR112012013164A2 (en) | 2016-03-01 |
| KR20120099751A (en) | 2012-09-11 |
| AU2010326633A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2506867B1 (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| CA2781493A1 (en) | Pharmaceutical compositions for the stimulation of stem cells | |
| KR101689415B1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| Luttun et al. | Vascular progenitors: from biology to treatment | |
| Shyu et al. | Homing genes, cell therapy and stroke | |
| US20040018174A1 (en) | Cell therapy for regeneration | |
| Sanganalmath et al. | Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond | |
| Zisa et al. | Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair | |
| Zisa et al. | Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells | |
| US20060110374A1 (en) | Method to accelerate stem cell recruitment and homing | |
| Jeon et al. | Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs | |
| Bulgin | Therapeutic angiogenesis in ischemic tissues by growth factors and bone marrow mononuclear cells administration: biological foundation and clinical prospects | |
| Lei et al. | Paracrining” the heart with stem cells | |
| Louzada et al. | Granulocyte-colony stimulating factor treatment of chronic myocardial infarction | |
| EP2432482B1 (en) | Pharmaceutical composition for the treatment of heart diseases. | |
| US20040166100A1 (en) | Treatment for arthritis | |
| Davis | The cell engraftment hypothesis of cardiac repair | |
| JP6923137B2 (en) | Tissue healing agent | |
| Širmenis et al. | Recovery of infarcted myocardium in an in vivo experiment | |
| Tateno et al. | Application of hematopoietic cells to therapeutic angiogenesis | |
| Zisa et al. | Intramuscular VEGF activates an SDF1-dependent progenitor cell 2 cascade and an SDF1-independent muscle paracrine cascade for 3 cardiac repair 4 | |
| Gojo et al. | Cardiac Regenerative Medicine Cellular Therapy and Tissue Engineering | |
| McDaniel et al. | Intramuscular VEGF activates an SDF1-dependent | |
| Steinhoff | Bone Marrow Stem Cell Treatment for Myocardial Regeneration | |
| Zimmermann | Emerging Concepts in Myocardial Pharmacoregeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20151202 |